Detecting MRD Prior to Repeat-transurethral Resection of Bladder Tumor in NMIBC
By Kyle M. Rose, MD - Last Updated: February 18, 2023Kyle M. Rose, MD, Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center & Research Institute, describes how cell-free urinary tumor DNA is used as a strategy to detect MRD prior to repeat-transurethral resection of bladder tumors in NMIBC.
Post Tags:ASCO GU 2023-Bladder Cancer
Related Posts
Phouc Tran, MD, PhD, highlights the challenges of accurate risk stratification for newly diagnosed localized prostate cancer.
Daniel M. Geynisman, MD, explains the results and utility of the RETAIN trial for bladder sparing in patients with MIBC.
Petros Grivas, MD, PhD, highlights the practice-changing studies that have come out of the ASCO GU 2023 Symposium.
Michael Atkins, MD, discusses TFS outcomes from the phase II study and argues for immunotherapy in favorable-risk patients.
Steven Campbell, MD, PhD, overviews the surgical options available for patients with localized renal cell carcinoma.
630 Madison Ave.
Manalapan, NJ 07726
© 2023 Mashup Media, LLC. All rights reserved.